Navigation Links
GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
Date:3/26/2009

Leading Sucralose manufacturer Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd. (GDFII/L&P) today announced that the U.S. International Trade Commission (ITC) in Washington D.C. has extended the target date of its final decision in the sucralose case, from March 25 to April 3. This Section 337 patent dispute (docket# 337-TA-604) was filed against the company by its main competitor, Tate & Lyle Corporation (T&L)

Exeter, California (PRWEB) March 26, 2009 -- Leading Sucralose manufacturer Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd. (GDFII/L&P) today announced that the U.S. International Trade Commission (ITC) in Washington D.C. has extended the target date of its final decision in the sucralose case, from March 25 to April 3. This Section 337 patent dispute (docket# 337-TA-604) was filed against the company by its main competitor, Tate & Lyle Corporation (T&L).

"GDFII/L&P was the first company to manufacture sucralose outside of the U.S.A and continues to be committed to meeting its customer needs of high capacity and superior grade sucralose in the growing sucralose market in the United States and elsewhere, and remains confident of a positive outcome once the ITC issues its final determination," notes Mr. Sanyong Wang, a corporate officer of GDFII/L&P.

Mr. Bassam Faress, spokesperson of GDFII/L&P and Director of Sales/Marketing at Ingredients Specialties, Inc., a global alliance partner of GDFII/L&P, adds "we continue to look forward to this anticipated positive final ruling as we move ahead with our strategic marketing and expansion plans for Sucralose."

The U.S. ITC governs investigations into allegations of unfair trade practices and had in its September 2008 initial determination issued by Administrative Law Judge Charles E. Bullock of the ITC, noted that GDFII/L&P has not violated any of the patents asserted in this Section 337 dispute. Furthermore, the Commission found one of the patents asserted by T&L to be invalid. Of the 4 patents asserted by T&L, one of the patents asserted was dropped before the hearing and following an inspection of GDFII/L&P's manufacturing facility; T&L's expert acknowledged that GDFII/L&P Food's current process, as inspected, did not infringe two of the other asserted patents; and a fourth patent expires in July 2009, only a few months after the new target date April 3rd for the ITC's final decision.

Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd. (GDFII/L&P) is a specialty ingredients manufacturer that pioneered the development and manufacturing of Sucralose at its ISO 9001:2000 and HACCP certified facility in China. In alliance with Ingredient Specialties, Inc. of Exeter, California, provides a global distribution network that markets Züeit ® brand Sucralose to the food, beverage, nutraceutical and pharmaceutical industries as a Kosher and Halal certified non-caloric high intensity sweetener. Züeit ® is a trademark of Ingredient Specialties, Inc. Exeter, CA, U.S.A.

# # #

Read the full story at http://www.prweb.com/releases/sucralose/sweetener/prweb2268614.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Mylan Confirms Four First-to-File Challenges
2. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
3. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
4. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
5. Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg
6. Brazilian Sugarcane Industry: OECD Report Confirms Overall Benefits of Brazilian Sugarcane Ethanol
7. ATS Medical Confirms Excellent Durability of the ATS Open Pivot Mechanical Heart Valve
8. Superior Patient Clinical Outcomes Confirms DaVitas Leadership Position on Quality Dialysis Care
9. ProMetic Further Confirms Performance of Prion Capture Resin at the Recovery of Biological Products Conference
10. Barr Confirms Patent Challenge of Prevacid(R) SoluTab(TM) Delayed-Release Orally Disintegrating Tablets, 15mg and 30mg
11. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity ... intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers at ... result of a collaboration among several companies with expertise in toolholding, cutting tools, ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):